Usui A
Department of Urology, Hiroshima University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1990 Jul;81(7):1051-7. doi: 10.5980/jpnjurol1989.81.1051.
The immune responses in patients with renal cell carcinoma were evaluated from the production of interleukin-2 (IL-2), the expression of IL-2 receptors and the activity of lymphokine activated killer (LAK) cells. In addition, the effect of the patient's serum on the expression of IL-2 receptors and LAK activity were investigated. The production of IL-2 by peripheral blood mononuclear cells (PBM) from patients with renal cell carcinoma was not suppressed, when compared with that in controls. However, the expression of IL-2 receptors tended to decrease with the progression of clinical stage. The LAK cells generated by PBM of patients with renal cell carcinoma had significant cytotoxic activity against Daudi cells, ACHN cells and autologous tumor cells, while autologous serum suppressed the expression of IL-2 receptors and the induction of LAK cells in patients with renal cell carcinoma. Furthermore, serum from patients with renal cell carcinoma suppressed the cytotoxic activity of LAK cells generated by PBM from a normal volunteer. These results indicated the presence of immunosuppressive factors in the serum of patients with renal cell carcinoma which impaired the clinical effect of treatment using IL-2 or LAK cells.
从白细胞介素-2（IL-2）的产生、IL-2受体的表达以及淋巴因子激活的杀伤（LAK）细胞的活性方面对肾细胞癌患者的免疫反应进行了评估。此外，还研究了患者血清对IL-2受体表达和LAK活性的影响。与对照组相比，肾细胞癌患者外周血单个核细胞（PBM）产生IL-2的能力未受到抑制。然而，IL-2受体的表达倾向于随着临床分期的进展而降低。肾细胞癌患者的PBM产生的LAK细胞对Daudi细胞、ACHN细胞和自体肿瘤细胞具有显著的细胞毒活性，而自体血清可抑制肾细胞癌患者IL-2受体的表达和LAK细胞的诱导。此外，肾细胞癌患者的血清可抑制正常志愿者的PBM产生的LAK细胞的细胞毒活性。这些结果表明肾细胞癌患者血清中存在免疫抑制因子，这些因子损害了使用IL-2或LAK细胞治疗的临床效果。
